文献速递胸部肿瘤

循环肿瘤DNA识别可从序贯TKI治疗获益的EGFR阳性NSCLC患者

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
PubMed 文献 · Eur J Cancer · 2021-04-05

该研究对228例IV期EGFR阳性NSCLC患者一线TKI治疗的830份血浆样本行dPCR分析,发现治疗前ctDNA的MAF<7%或治疗3/6个月ctDNA阴性且诊断时MAF<7%的患者,一线一代/二代TKI治疗后死亡风险显著降低,且与 upfront 奥希替尼相比OS无显著差异。

要点

  • 治疗前ctDNA MAF<7%或3/6个月ctDNA清除者可从序贯TKI治疗获益。
  • 低风险患者一线一代/二代TKI后中位OS为34.2个月,高应答者未达到。
  • 低风险或高应答者中,upfront奥希替尼与序贯奥希替尼的OS无显著差异。

核心结论

  • 治疗前ctDNA水平可识别低风险患者,这些患者可能从序贯TKI治疗中获益。
  • EGFR突变清除信息有助于改善患者选择。

研究设计与样本

  • 回顾性分析228例IV期EGFR阳性NSCLC患者一线TKI治疗的830份血浆样本,采用数字PCR检测ctDNA。

主要发现

  • 一线一代/二代TKI治疗患者中,治疗前MAF<7%者(低风险)死亡风险调整HR=0.38(95%CI 0.23-0.64)。
  • 治疗3或6个月ctDNA阴性且诊断时MAF<7%者(高应答)调整HR=0.22(95%CI 0.12-0.42)。
  • 低风险患者中位OS为34.2个月,高应答者中位OS未达到。
  • 低风险或高应答患者中,upfront奥希替尼(N=39)与序贯奥希替尼(N=60)的OS无显著差异,两组中位OS均未达到。

关键数值与推荐

  • 低风险定义:治疗前血浆EGFR突变MAF<7%。
  • 高应答定义:治疗3或6个月ctDNA阴性且诊断时MAF<7%。

临床怎么用

  • 可通过治疗前及治疗中ctDNA动态监测识别可能从序贯TKI治疗中获益的低风险EGFR阳性NSCLC患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survival data support the use of first-line osimertinib as the standard of care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). However, it remains unclear whether upfront osimertinib is superior to sequential first- or second-generation tyrosine kinase inhibitors (TKIs) followed by osimertinib for all patients. It is impossible to predict which patients are at high risk of progression, and this constitutes a major limitation of the sequential TKI approach. PATIENTS AND METHODS: A total of 830 plasma samples from 228 patients with stage IV, EGFR-positive NSCLC who were treated with first-line TKIs were analysed by digital polymerase chain reaction (dPCR). RESULTS: The circulating tumour DNA (ctDNA) levels helped to identify patients with significantly improved survival rate, regardless of the treatment. Patients treated with first- or second-generation TKIs (N = 189) with EGFR mutations in plasma at a mutant allele frequency (MAF) <7% before treatment initiation (low-risk patients) or who were ctDNA negative after 3 or 6 months of treatment and with an MAF <7% at diagnosis (high responders) had two-thirds lower risk of death than patients in the opposite situation (adjusted hazard ratio [HR] = 0.38; 95% confidence interval [CI]: 0.23-0.64 and HR = 0.22; 95% CI: 0.12-0.42, respectively). The median overall survival (OS) for low-risk patients and high responders treated with first- or second-generation TKIs was 34.2 months and not reached, respectively, regardless of second-line treatment. There were no significant difference in OS between low-risk or high-responder patients treated upfront with osimertinib (N = 39) and those treated under a sequential approach with osimertinib (N = 60). Median OS was not reached in both cases. CONCLUSIONS: Pre-treatment ctDNA levels identify low-risk patients, who may benefit from sequential TKI treatment. Information regarding EGFR mutation clearance can help to improve patient selection.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Provencio M, Serna-Blasco R, Franco F, et al. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. Eur J Cancer. 2021. PMID: 33831609. doi:10.1016/j.ejca.2021.02.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。